US approves Teva’s cancer treatment

The US FDA’s oncology committee has approved CT-P10 – Teva’s monoclonal antibody biosimilar to Rituxan (rituximab) for the treatment of various forms of cancer. The development of biosimilars has the potential to increase accessibility to therapies for patients.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *